Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT05575440
Overview
This phase II study evaluates F-18 tetrafluoroborate (18F-TFB) PET/CT scan in patients with differentiated thyroid cancer. Diagnostic imaging is necessary for planning treatment, monitoring therapy response, and identifying sites of recurrent or metastatic disease in differentiated thyroid cancer. 18F-TFB PET/CT may accurately detect recurrent and metastatic thyroid cancer lesions, with the potential to provide information for patient management that is better than the current standard of care imaging practices.
Sponsor
Mayo Clinic
Phase
N/A
Contacts
Clinical Trials Referral Office
mayocliniccancerstudies@mayo.edu
855-776-0015
ClinicalTrials.gov
NCT05575440Drug / Compound
Help us improve your experience